Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03935893 · ClinicalTrials.gov registry record · Phase 2
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid Cancers
A Phase 2 study of Colorectal Cancer and Pancreatic Cancer, sponsored by Udai Kammula.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 240
- Enrollment target
- 1
- Study location
NCT03935893 is a Phase 2 study of Colorectal Cancer and Pancreatic Cancer that is actively recruiting participants, run by Udai Kammula. The registered enrollment target is 240 participants, below the 1,511-participant average among 369 other Colorectal Cancer trials with a reported enrollment target (84% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03935893, a Phase 2 study of Colorectal Cancer and Pancreatic Cancer, is actively recruiting participants, sponsored by Udai Kammula.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 240 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a Phase 2 study to evaluate the efficacy of a non-myeloablative lymphodepleting preparative regimen followed by infusion of autologous TIL and high-dose aldesleukin in patients with locally advanced, recurrent, or metastatic cancer associated with one of the following cancer types: 1.) gastric/esophagogastric, 2.) colorectal, 3.) pancreatic, 4.) sarcoma, 5.) mesothelioma, 6.) neuroendocrine, 7.) squamous cell cancer, 8.) Merkle cell, 9.) mismatch repair deficient and/or microsatellite unstable cancers, and 10.) patients who have exhausted conventional systemic therapy options by using the objective response rate (ORR).
Conditions Studied
Interventions
- BIOLOGICAL Tumor Infiltrating Lymphocytes (TIL)
- DRUG Fludarabine + Cyclophosphamide combination
Study Locations (1)
Pennsylvania
- UPMC Hillman Cancer Center - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 240 participants |
| Start Date | 2019-12-03 |
| Est. Completion | 2038-06-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03935893
The ClinicalTrials.gov registry entry for NCT03935893 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 240 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,511-participant average among 369 other Colorectal Cancer trials with a reported enrollment target (84% lower). The listed sponsor is Udai Kammula, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 10 conditions, with Colorectal Cancer appearing as the primary indexed condition, and to 2 interventions - of which Tumor Infiltrating Lymphocytes (TIL) is the first listed.
NCT03935893 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT03935893 about?
NCT03935893 is a clinical study titled "Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid Cancers". This is a Phase 2 study to evaluate the efficacy of a non-myeloablative lymphodepleting preparative regimen followed by infusion of autologous TIL and high-dose aldesleukin in patients with locally advanced, recurrent, or metastatic cancer associated with one of the following cancer types: 1.) gastr...
What is the current status of trial NCT03935893?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 240 participants. The study started on 2019-12-03. Estimated completion is 2038-06-30.
What conditions does trial NCT03935893 study?
This clinical trial studies the following conditions: Colorectal Cancer, Pancreatic Cancer, Gastric Cancer, Sarcoma, Neuroendocrine Tumors.
What interventions are being tested in trial NCT03935893?
The interventions under investigation include: Tumor Infiltrating Lymphocytes (TIL) (BIOLOGICAL), Fludarabine + Cyclophosphamide combination (DRUG).
Who is sponsoring clinical trial NCT03935893?
This trial is sponsored by Udai Kammula, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03935893 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Colorectal Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Assess Adverse Events and Change in Disease Activity in Adult Participants Receiving Intravenously Infused Telisotuzumab Adizutecan Alone or With Standard of Care in Participants With Post Adjuvant Circulating Tumor DNA Positive Colorectal Cancer and No Radiographic Evidence of Disease
RECRUITING · Phase 2
-
A Study of Single Fraction Stereotactic Body Radiation Therapy (SBRT) Guided by Magnetic Resonance Imaging (MRI) in People With Liver Metastasis From Colorectal Cancer
RECRUITING · Phase 2
-
TAS-102 With or Without Celecoxib in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy
RECRUITING · Phase 2
-
A Phase 2 Trial of Fruquintinib and Tislelizumab in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy
RECRUITING · Phase 2
-
A Study of IBI363 in Subjects with Advanced Solid Malignancies
RECRUITING · Phase 2
-
Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.